Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melanoma.

F G Haluska1, P S Multani

  • 1Hematology/Oncology Fellowship Training Program, Massachusetts General Hospital, Boston 02114, USA.

Cancer Chemotherapy and Biological Response Modifiers
|May 9, 2000
PubMed
Summary
This summary is machine-generated.

Conventional melanoma treatments are often ineffective. While some cytokine therapies show promise, their significant toxicities necessitate further research into immunotherapy and active immunization strategies for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

The New England journal of medicine·2013
Same author

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

Oncogene·2009
Same author

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.

The oncologist·2001
Same author

Patient preferences for adjuvant interferon alfa-2b treatment.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.

Cellular immunology·2000
Same author

Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.

Archives of dermatology·2000
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Conventional therapies for melanoma, including cytotoxic chemotherapies, have yielded unsatisfactory results.
  • Previous studies indicate that response rates from single-institution Phase II trials may not be reproducible in multi-institution settings.

Purpose of the Study:

  • To review the efficacy and limitations of current melanoma treatment modalities.
  • To explore the potential of cytokine therapy and immunotherapy as alternative treatment strategies for melanoma.

Main Methods:

  • Review of existing randomized studies and clinical trial data on melanoma treatments.
  • Analysis of the utility and toxicity profiles of cytokine therapies like interferon-alpha and interleukin-2.
  • Evaluation of the rationale for pursuing immunotherapy approaches.

Related Experiment Videos

Main Results:

  • Cytokine therapy (interferon-alpha, interleukin-2) has shown some utility but is associated with formidable toxicities.
  • Limited successes with current immunomodulatory strategies highlight the need for further investigation.
  • Response rates from early-phase trials are not consistently generalizable to broader clinical settings.

Conclusions:

  • Immunotherapy, particularly active immunization protocols, represents a promising avenue for future melanoma treatment research.
  • Continued investigation into refining immunotherapy is warranted to overcome the limitations of conventional and current cytokine-based therapies.